NASDAQ:KURA - Kura Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.36 -0.47 (-2.97 %) (As of 03/21/2019 06:00 AM ET)Previous Close$15.83Today's Range$15.3260 - $15.9052-Week Range$10.20 - $22.00Volume85,417 shsAverage Volume217,230 shsMarket Capitalization$586.28 millionP/E Ratio-8.93Dividend YieldN/ABeta2.9 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California. Receive KURA News and Ratings via Email Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA Previous Symbol CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone858-500-8800Debt Debt-to-Equity Ratio0.05 Current Ratio13.31 Quick Ratio13.31Price-To-Earnings Trailing P/E Ratio-8.93 Forward P/E Ratio-8.04 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book3.64Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-60,450,000.00 Net MarginsN/A Return on Equity-42.21% Return on Assets-37.49%Miscellaneous EmployeesN/A Outstanding Shares38,169,000Market Cap$586.28 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Kura Oncology (NASDAQ:KURA) Frequently Asked Questions What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." How were Kura Oncology's earnings last quarter? Kura Oncology Inc (NASDAQ:KURA) announced its earnings results on Tuesday, March, 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.01. View Kura Oncology's Earnings History. When is Kura Oncology's next earnings date? Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Kura Oncology. What price target have analysts set for KURA? 4 Wall Street analysts have issued twelve-month price objectives for Kura Oncology's shares. Their predictions range from $25.00 to $32.00. On average, they expect Kura Oncology's stock price to reach $29.3333 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View Analyst Price Targets for Kura Oncology. What is the consensus analysts' recommendation for Kura Oncology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology. What are Wall Street analysts saying about Kura Oncology stock? Here are some recent quotes from research analysts about Kura Oncology stock: 1. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (1/8/2019) 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/3/2018) Has Kura Oncology been receiving favorable news coverage? Media stories about KURA stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kura Oncology earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the immediate future. Who are some of Kura Oncology's key competitors? Some companies that are related to Kura Oncology include Arena Pharmaceuticals (ARNA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Madrigal Pharmaceuticals (MDGL), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), PTC Therapeutics (PTCT), Nabriva Therapeutics (NBRV), Ironwood Pharmaceuticals (IRWD), Enanta Pharmaceuticals (ENTA), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT) and The Medicines (MDCO). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Advanced Micro Devices (AMD), Viking Therapeutics (VKTX), Novavax (NVAX), Fate Therapeutics (FATE), NVIDIA (NVDA), Rigel Pharmaceuticals (RIGL), Sophiris Bio (SPHS) and Catalyst Pharmaceuticals (CPRX). Who are Kura Oncology's key executives? Kura Oncology's management team includes the folowing people: Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)Dr. Marc Grasso, CFO & Chief Bus. OfficerMr. John Farnam, Chief Operating OfficerMr. Pete De Spain, VP of Investor Relations & Corp. Communications Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include Great Point Partners LLC (7.28%), BlackRock Inc. (6.34%), Eagle Asset Management Inc. (5.35%), Victory Capital Management Inc. (4.45%), Partner Fund Management L.P. (3.01%) and Northern Trust Corp (0.99%). View Institutional Ownership Trends for Kura Oncology. Which institutional investors are selling Kura Oncology stock? KURA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Eagle Asset Management Inc., Bank of America Corp DE, Squarepoint Ops LLC, MetLife Investment Advisors LLC, Raymond James & Associates, WINTON GROUP Ltd and Virtus ETF Advisers LLC. View Insider Buying and Selling for Kura Oncology. Which institutional investors are buying Kura Oncology stock? KURA stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Fosun International Ltd, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Victory Capital Management Inc., California Public Employees Retirement System, Citigroup Inc. and Prosight Management LP. View Insider Buying and Selling for Kura Oncology. How do I buy shares of Kura Oncology? Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $15.36. How big of a company is Kura Oncology? Kura Oncology has a market capitalization of $586.28 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. What is Kura Oncology's official website? The official website for Kura Oncology is http://www.kuraoncology.com. How can I contact Kura Oncology? Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected] MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 206 (Vote Underperform)Total Votes: 459MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low?